Lymphoma is a large class of blood cancers that affect the lymphoid system, which is part of the immune system. In 2006, lymphoma affected an estimated 500,000 people in the United States, with 332,000 of them suffering from non-Hodgkin's varieties of the disease. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma and is generally categorized as aggressive, marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow and other organs.
A variety of treatment options exist, including chemotherapy and radiation, but the five-year survival rate for non-Hodgkin's lymphoma patients is estimated to be around 50%. Even for those who respond to treatment, recurrence of the disease is common.
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
This press release contains "forward-looking" statements,
including statements related to Rigel's plans to pursue clinical
development of product candidates, the timing of results thereof
and the potentia